Gain Therapeutics (NASDAQ:GANX) Issues Earnings Results

Gain Therapeutics (NASDAQ:GANX) released its quarterly earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.05, Zacks reports.

Gain Therapeutics Price Performance

GANX stock traded up $0.04 during trading on Wednesday, reaching $1.12. 105,730 shares of the company were exchanged, compared to its average volume of 708,562. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.36 and a current ratio of 4.36. The stock’s 50 day moving average price is $1.51 and its 200 day moving average price is $1.83. Gain Therapeutics has a 52-week low of $0.94 and a 52-week high of $4.34. The company has a market cap of $49.09 million, a P/E ratio of -2.24 and a beta of 0.29.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on GANX shares. BTIG Research reiterated a “buy” rating and set a $5.00 target price on shares of Gain Therapeutics in a research note on Monday, October 5th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research report on Monday, October 5th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Friday, September 4th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $7.67.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc. is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms. Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease.